INLYTA is an oral therapy designed to selectively inhibit vascular endothelial growth factor receptors 1, 2 and 3, which can influence tumor growth, vascular angiogenesis and progression of cancer.
The Phase III AXIS trial data has demonstrated that INLYTA extended progression free survival with a median PFS of 6.7 months compared with 4.7 months for those treated with sorafenib.
Pfizer oncology business unit president and general manager Garry Nicholson said INLYTA is an important addition to the portfolio of treatment options for patients with advanced RCC.
Pfizer oncology business unit clinical development and medical affairs senior vice president Mace Rothenberg said INLYTA is the first targeted therapy to be approved in US for advanced RCC patients.